CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30
CITIUS ONCOLOGY, INC.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.71−0.06 (-7.49%)
Close on Oct 19, 2026
- Market cap
- $76.65M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
15.2%
14M of 93M shares
Institutional holders
19
7 new, 2 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 9,353,553 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Steven Boyd | 7,675,911 | 9.79% | 13G (passive) | Sep 30, 2025 |
| Citius Pharmaceuticals, Inc. | 66,049,615 | 71.00% | 13D (active) amendment | May 15, 2026 |
| Mizuho Financial Group, Inc. | 522,030 | 5.84% | 13G (passive) | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CTOR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 8,705,589 | 9.36% | $5.66M | −483,266 | 0.07% |
| Bank Of America Corp /De/ | 3,835,160 | 4.12% | $2.49M | – | 0.00% |
| Vanguard Capital Management LLC | 546,325 | 0.59% | $355.11K | +11,501 | 0.00% |
| UBS Group AG | 334,619 | 0.36% | $217.50K | +297,779 | 0.00% |
| Geode Capital Management, LLC | 245,407 | 0.26% | $159.54K | −19,326 | 0.00% |
| Vanguard Fiduciary Trust Co | 121,910 | 0.13% | $79.24K | – | 0.00% |
| IFP Advisors, Inc | 107,424 | 0.12% | $69.84K | – | 0.00% |
| Citadel Advisors LLC | 90,586 | 0.10% | $58.89K | New | 0.00% |
| Northern Trust Corp | 45,746 | 0.05% | $29.74K | – | 0.00% |
| State Street Corp | 42,900 | 0.05% | $27.89K | – | 0.00% |
| Virtu Financial LLC | 21,877 | 0.02% | $14 | New | 0.00% |
| XTX Topco Ltd | 20,638 | 0.02% | $13.42K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 13,816 | 0.01% | $8.98K | New | 0.00% |
| Arkadios Wealth Advisors | 11,666 | 0.01% | $7.58K | – | 0.00% |
| Osaic Holdings, Inc. | 1,000 | 0.00% | $650 | −9,125 | 0.00% |
| Wells Fargo & Company/Mn | 500 | 0.00% | $325 | New | 0.00% |
| Barclays PLC | 90 | 0.00% | $59 | New | 0.00% |
| Morgan Stanley | 23 | 0.00% | $15 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | 0.00% | $1 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 19 | 14M | 15.2% | 7 / 2 | 3 / 2 | 0M | 1M |
| Q1 2026 | 14 | 14M | 15.3% | 3 / 7 | 1 / 6 | 8M | 0M |
| Q4 2025 | 18 | 7M | 7.4% | 6 / 5 | 4 / 4 | 1M | 2M |
| Q3 2025 | 16 | 8M | 9.0% | 10 / 3 | 2 / 1 | 8M | 0M |
| Q2 2025 | 7 | 0M | 0.2% | 2 / 3 | 1 / 1 | 0M | 0M |
| Q1 2025 | 6 | 0M | 0.1% | 0 / 2 | 1 / 5 | 0M | 0M |
| Q4 2024 | 11 | 0M | 0.2% | 5 / 2 | 1 / 1 | 0M | 0M |
| Q3 2024 | 7 | 0M | 0.0% | 7 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CTOR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 370,100 | 0.40% | $240.60K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 176,225 | 0.19% | $114.56K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 112,734 | 0.12% | $89.96K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 57,297 | 0.06% | $45.72K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 26,290 | 0.03% | $20.98K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 23,392 | 0.03% | $18.67K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Leonard L. Mazur | Chief Executive Officer, Director | 1,700,000 | 1.83% | Dec 22, 2025 |
| Myron Z. Holubiak | Secretary, Director | 950,000 | 1.02% | Dec 22, 2025 |
| Jaime Bartushak | Chief Financial Officer | 825,000 | 0.89% | Dec 22, 2025 |
| Myron Czuczman | Chief Medical Officer | 825,000 | 0.89% | Dec 22, 2025 |
| Jonathan Peri | Director | 0 | – | Aug 14, 2026 |
| Dennis M. McGrath | Director | 300,000 | 0.32% | Dec 22, 2025 |
| Robert Joseph Smith | Director | 300,000 | 0.32% | Dec 22, 2025 |
| Suren G. Dutia | Director | 300,000 | 0.32% | Dec 22, 2025 |
| Eugene Myron Holuka | Director | 300,000 | 0.32% | Dec 22, 2025 |
| Carol Webb | Director | 300,000 | 0.32% | Dec 22, 2025 |
| Joel David Mayersohn | Director | 321,228 | 0.35% | Dec 22, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Myron Z. Holubiak Secretary, Director | Sep 19, 2025 | Award | +850,000 | – | – | 850,000 |
| Leonard L. Mazur Chief Executive Officer, Director | Sep 19, 2025 | Award | +1,700,000 | – | – | 1,700,000 |
| Jaime Bartushak Chief Financial Officer | Sep 19, 2025 | Award | +825,000 | – | – | 825,000 |
| Robert Joseph Smith Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Dennis M. McGrath Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Carol Webb Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Suren G. Dutia Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Myron Czuczman Chief Medical Officer | Sep 19, 2025 | Award | +825,000 | – | – | 825,000 |
| Eugene Myron Holuka Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Joel David Mayersohn Director | Sep 19, 2025 | Award | +300,000 | – | – | 321,228 |
| Myron Czuczman Chief Medical Officer | Sep 19, 2025 | Award | +825,000 | – | – | 825,000 |
| Robert Joseph Smith Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Dennis M. McGrath Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Joel David Mayersohn Director | Sep 19, 2025 | Award | +300,000 | – | – | 321,228 |
| Leonard L. Mazur Chief Executive Officer, Director | Sep 19, 2025 | Award | +1,700,000 | – | – | 1,700,000 |
| Myron Z. Holubiak Secretary, Director | Sep 19, 2025 | Award | +850,000 | – | – | 850,000 |
| Jaime Bartushak Chief Financial Officer | Sep 19, 2025 | Award | +825,000 | – | – | 825,000 |
| Carol Webb Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Suren G. Dutia Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Eugene Myron Holuka Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Carol Webb Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Robert Joseph Smith Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Leonard L. Mazur Chief Executive Officer, Director | Sep 19, 2025 | Award | +1,700,000 | – | – | 1,700,000 |
| Myron Z. Holubiak Secretary, Director | Sep 19, 2025 | Award | +100,000 | – | – | 100,000 |
| Myron Z. Holubiak Secretary, Director | Sep 19, 2025 | Award | +850,000 | – | – | 850,000 |
| Eugene Myron Holuka Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Myron Czuczman Chief Medical Officer | Sep 19, 2025 | Award | +825,000 | – | – | 825,000 |
| Joel David Mayersohn Director | Sep 19, 2025 | Award | +300,000 | – | – | 321,228 |
| Suren G. Dutia Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Dennis M. McGrath Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Jaime Bartushak Chief Financial Officer | Sep 19, 2025 | Award | +825,000 | – | – | 825,000 |
| Joel David Mayersohn Director | Jul 28, 2025 | Other | +21,228 | – | – | 21,228 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.